Clinical Trial Update: Safety and Efficacy of CRS-207 With Pembrolizumab in Gastric, Gastroesophageal Junction or Esophageal Cancers [Phase 2]

View source ↗

Summary

Phase 2 trial assessing CRS-207 with pembrolizumab in gastric, gastroesophageal junction, and esophageal adenocarcinomas; study terminated with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Adenocarcinoma
• Gastric Adenocarcinoma
• Gastroesophageal Junction Adenocarcinoma

Drugs mentioned

• CRS-207
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Aduro Biotech, Inc. | Conditions: Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma | Phase 2 | Status: TERMINATED | Results posted: 2019-02-20